Pharma Sector Should Push Manufacturing Patents for Biologics
October 4, 2023
Read time: 2 min
In this article, Michael Siekman and Brennen Baylor analyze the value of manufacturing patents for biologics and why companies should reevaluate their patent prosecution strategy.
Do not send any information or documents that you want to have treated as secret or confidential. Providing information to McDermott Will & Schulte via email links on this website or other introductory email communications will not create an attorney-client relationship; will not preclude McDermott Will & Schulte from representing any other person or firm in any matter; and will not obligate McDermott Will & Schulte to keep confidential the information you provide. McDermott Will & Schulte cannot enter into an attorney-client relationship with you until McDermott Will & Schulte has determined that doing so will not create a conflict of interest and until you and McDermott Will & Schulte have entered into a written agreement or engagement letter that sets forth the terms of our relationship.
